

3 April 2024

## Privatisation by way of scheme of arrangement

## Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description	Nature of dealings	Purchase /	Total	Total amount	Highest (H)	Lowest (L)
		of relevant		Sale	number	paid / received	prices paid	prices paid
		securities			of		/ received	/ received
					shares			
					involved			
CICC	2 April 2024	Other types	Closing / flattening / unwinding of	Sale	167,500	\$2,977,370.6200	\$17.7753	\$17.7753
Wealth		of securities	proprietary positions arising from					
Investment		(e.g. equity	unsolicited client-driven dealings. I					
Limited		swaps)	confirm this was done no later than					
			the close of the morning trading					
			session on the trading day following					
			the orginating client-driven dealing					



Other types	Closing / flattening / unwinding of	Purchase	167,500	\$2,976,729.6000	\$17.7715	\$17.7715
of securities	proprietary positions arising from					
(e.g. equity	unsolicited client-driven dealings. I					
swaps)	confirm this was done no later than					
	the close of the morning trading					
	session on the trading day following					
	the orginating client-driven dealing					

End

Note:

CICC Wealth Investment Limited is an exempt principal trader connected with the Offeree company.

Dealings were made for its own account.

CICC Wealth Investment Limited is ultimately owned by China International Capital Corporation Limited.